Regulation of 4-HNE via SMARCA4 Is Associated with Worse Clinical Outcomes in Hepatocellular Carcinoma

Accumulation of 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation, has various favorable and unfavorable effects on cancer cells; however, the clinicopathological significance of its accumulation in hepatocellular carcinoma (HCC) and its metabolic pathway remain unknown. This study analyzed 4-HNE accumulation and its clinicopathological significance in HCC. Of the 221 cases, 160 showed relatively low accumulation of 4-HNE in HCC tissues, which was an independent prognostic predictor. No correlation was found between 4-HNE accumulation and the expression of the antioxidant enzymes glutathione peroxidase 4, ferroptosis suppressor protein 1, and guanosine triphosphate cyclohydrolase 1. Therefore, we hypothesized that 4-HNE metabolism is up-regulated in HCC. A database search was focused on the transcriptional regulation of aldo-keto reductases, alcohol dehydrogenases, and glutathione-S-transferases, which are the metabolic enzymes of 4-HNE, and seven candidate transcription factor genes were selected. Among the candidate genes, the knockdown of SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 (SMARCA4) increased 4-HNE accumulation. Immunohistochemical analysis revealed an inverse correlation between 4-HNE accumulation and SMARCA4 expression. These results suggest that SMARCA4 regulates 4-HNE metabolism in HCC. Therefore, targeting SMARCA4 provides a basis for a new therapeutic strategy for HCC via 4-HNE accumulation and increased cytotoxicity.

[1]  Kellen L. Olszewski,et al.  A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers , 2022, Nature Communications.

[2]  M. Kitagawa,et al.  Stratification of lung squamous cell carcinoma based on ferroptosis regulators: Potential for new therapeutic strategies involving ferroptosis induction. , 2022, Lung cancer.

[3]  Wei Liu,et al.  Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma , 2021, Journal of hepatocellular carcinoma.

[4]  Jin Choul Chai,et al.  BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4 , 2021, Scientific Reports.

[5]  B. Firestein,et al.  Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation , 2021, Cells.

[6]  Xue-Hai Zhu,et al.  Posttranslational Modifications in Ferroptosis , 2020, Oxidative medicine and cellular longevity.

[7]  M. Kitagawa,et al.  SECISBP2 is a novel prognostic predictor that regulates selenoproteins in diffuse large B-cell lymphoma , 2020, Laboratory Investigation.

[8]  Jiaqi Xu,et al.  The Role of BRG1 in Antioxidant and Redox Signaling , 2020, Oxidative medicine and cellular longevity.

[9]  S. Hewitt,et al.  4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept , 2020, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  N. Miyasaka,et al.  High amplification of PVT1 and MYC predict favorable prognosis in early ovarian carcinoma. , 2020, Pathology, research and practice.

[11]  C. Roberts,et al.  The SWI/SNF complex in cancer — biology, biomarkers and therapy , 2020, Nature Reviews Clinical Oncology.

[12]  Kairong Cui,et al.  Oncogene-dependent function of BRG1 in hepatocarcinogenesis , 2020, Cell Death and Disease.

[13]  B. Stockwell,et al.  GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis through Lipid Remodeling , 2019, ACS central science.

[14]  Edward W. Tate,et al.  FSP1 is a glutathione-independent ferroptosis suppressor , 2019, Nature.

[15]  J. Olzmann,et al.  The CoQ oxidoreductase FSP1 acts in parallel to GPX4 to inhibit ferroptosis , 2019, Nature.

[16]  Jun Sese,et al.  ChIP‐Atlas: a data‐mining suite powered by full integration of public ChIP‐seq data , 2018, EMBO reports.

[17]  P. A. Futreal,et al.  Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer , 2018, Nature Medicine.

[18]  M. Kitagawa,et al.  Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma , 2018, Laboratory Investigation.

[19]  R. Schulte‐Hermann,et al.  Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma , 2018, Oncotarget.

[20]  Di Chen,et al.  Hepatic SMARCA4 predicts HCC recurrence and promotes tumour cell proliferation by regulating SMAD6 expression , 2018, Cell Death & Disease.

[21]  L. Milković,et al.  Cancer growth regulation by 4‐hydroxynonenal , 2017, Free radical biology & medicine.

[22]  A. Gęgotek,et al.  Antioxidants and HNE in redox homeostasis. , 2017, Free radical biology & medicine.

[23]  F. Guéraud.  4-Hydroxynonenal metabolites and adducts in pre-carcinogenic conditions and cancer. , 2017, Free radical biology & medicine.

[24]  Stuart L. Schreiber,et al.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.

[25]  Ying Zhang,et al.  Expression of 4-hydroxynonenal in esophageal squamous cell carcinoma , 2017, Oncology letters.

[26]  X. Mao,et al.  Glutathione-s-transferase A 4 (GSTA4) suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting AKT pathway. , 2017, American journal of translational research.

[27]  N. Žarković,et al.  Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells , 2016, Redox biology.

[28]  T. Herman,et al.  Glutathione S-transferase alpha 4 induction by activator protein 1 in colorectal cancer , 2016, Oncogene.

[29]  S. Costantini,et al.  GPX4 and GPX7 Over-Expression in Human Hepatocellular Carcinoma Tissues , 2015, European journal of histochemistry : EJH.

[30]  N. Girard,et al.  SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas , 2015, Nature Genetics.

[31]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[32]  H. Yin,et al.  Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: Focusing on mitochondria , 2014, Redox biology.

[33]  Jason J. Corneveaux,et al.  Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4 , 2014, Nature Genetics.

[34]  Matthew E. Welsch,et al.  Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.

[35]  L. Huc,et al.  Cell death and diseases related to oxidative stress:4-hydroxynonenal (HNE) in the balance , 2013, Cell Death and Differentiation.

[36]  Dan Li,et al.  Aldo–keto reductases mediate constitutive and inducible protection against aldehyde toxicity in human neuroblastoma SH-SY5Y cells , 2013, Neurochemistry International.

[37]  S. Lightfoot,et al.  4-hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages. , 2012, Gastroenterology.

[38]  G. Muzio,et al.  Aldehyde dehydrogenases and cell proliferation. , 2012, Free radical biology & medicine.

[39]  S. Post,et al.  Expression of selenium-containing proteins in human colon carcinoma tissue. , 2011, Anticancer research.

[40]  Peng Huang,et al.  Metabolic alterations in cancer cells and therapeutic implications , 2011, Chinese journal of cancer.

[41]  D. Whittington,et al.  Glutathione transferase A4-4 resists adduction by 4-hydroxynonenal. , 2010, Archives of biochemistry and biophysics.

[42]  T. Kensler,et al.  When NRF2 talks, who's listening? , 2010, Antioxidants & redox signaling.

[43]  P. D. Josephy,et al.  Genetic Variations in Human Glutathione Transferase Enzymes: Significance for Pharmacology and Toxicology , 2010, Human genomics and proteomics : HGP.

[44]  J. O’Sullivan,et al.  Levels of oxidative damage and lipid peroxidation in thyroid neoplasia , 2009, Head & neck.

[45]  Y. Awasthi,et al.  4-Hydroxynonenal self-limits fas-mediated DISC-independent apoptosis by promoting export of Daxx from the nucleus to the cytosol and its binding to Fas. , 2008, Biochemistry.

[46]  I. Rusyn,et al.  Predictive Power of Biomarkers of Oxidative Stress and Inflammation in Patients with Hepatitis C Virus-Associated Hepatocellular Carcinoma , 2007, Annals of Surgical Oncology.

[47]  M. Tang,et al.  Trans-4-hydroxy-2-nonenal inhibits nucleotide excision repair in human cells: a possible mechanism for lipid peroxidation-induced carcinogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Y. Awasthi,et al.  Role of 4-hydroxynonenal in stress-mediated apoptosis signaling. , 2003, Molecular aspects of medicine.

[49]  R. Schaur,et al.  Basic aspects of the biochemical reactivity of 4-hydroxynonenal. , 2003, Molecular aspects of medicine.

[50]  M. Tang,et al.  The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. , 2002, Carcinogenesis.

[51]  N. Žarković,et al.  Associated changes of lipid peroxidation and transforming growth factor β1 levels in human colon cancer during tumour progression , 2002, Gut.

[52]  S. Toyokuni,et al.  Localization of hydroxynonenal protein adducts in normal human kidney and selected human kidney cancers. , 1999, Free radical biology & medicine.

[53]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[54]  Shimin Zhao,et al.  Metabolic changes in cancer: beyond the Warburg effect. , 2013, Acta biochimica et biophysica Sinica.